Changes in Hong Kong stocks | China Biopharmaceutical (01177) rose nearly 5% in early trading TQB6426 was approved by the FDA for clinical use in the treatment of advanced malignant tumors

The Zhitong Finance App learned that China Biopharmaceuticals (01177) rose nearly 5% in early trading. As of press release, it rose 3.99% to HK$5.47, with a turnover of HK$107 million.

According to the news, TQB6426, an innovative GPC3 antibody drug conjugate (ADC) independently developed by Zhengda Tianqing, a subsidiary of China Biopharmaceutical, recently obtained a default clinical trial license from the US Food and Drug Administration (FDA) and is intended for treatment of advanced malignant tumors. At this point, TQB6426 has obtained clinical entry qualifications for the two core pharmaceutical markets in China and the US, becoming an important milestone in the company's global development of innovative drugs.

Furthermore, Chia Tai Tianqing announced that the results of its self-developed phase III clinical study of TQB2102, a new dual-antibody ADC drug that can be used to treat recurrent/metastatic breast cancer with low HER2 expression, have been determined by an independent data monitoring committee to reach the intended end point. According to reports, this is the first innovative drug of its kind in the world to successfully complete phase III clinical research. It is expected to achieve accurate treatment for breast cancer patients and provide new treatment options for breast cancer patients with specific molecular types.